Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Regeneron Acquires Sanofi Ophthalmology Programs | Contract Pharma

What are you searching for?

Sign in
Breaking News

Regeneron Acquires Sanofi Ophthalmology Programs

Deal worth as much as $50 million, plus royalties

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Regeneron Pharmaceuticals has expanded its ophthalmology portfolio, acquiring exclusive rights to two antibodies invented at Regeneron and previously part of its collaboration with Sanofi. The antibodies target the PDGF (platelet derived growth factor) family of receptors and ligands in ophthalmology and all other indications. Antibodies to PDGF and ANG2 are currently in preclinical development for use in ophthalmology.
 
Regeneron will pay Sanofi $10 million upfront, as much as $40 million in development milestones, and royalties on sales. With respect to ANG2 antibodies in ophthalmology, Regeneron will pay Sanofi $10 million upfront, a potential $5 million development milestones, and royalties on sales.
 
Regeneron and Sanofi will continue to develop Antibodies to ANG2 outside of ophthalmology under their antibody collaboration agreement, including REGN910 (SAR 307746), which is currently in Phase I development in patients with advanced malignancies.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics